On 23 April, Vienna hosted the 5th Virus Safety Workshop, organised by ViruSure, an international meeting that brought together experts from the biopharmaceutical sector to discuss viral safety, manufacturing platforms and regulatory challenges in the development of vaccines and biologics.
In this context, Clara Panosa, R&D Manager of the Human Health Division at HIPRA, participated as a speaker with a presentation focused on platform-based vaccine manufacturing and its role in the rapid adaptation to new variants. She also had the opportunity to share the meeting with leading organisations in the sector such as Takeda, the Paul-Ehrlich-Institut and AGES (Austrian Agency for Health and Food Safety).
The session in which she participated, entitled “Platform Vaccine Manufacturing for Rapid Variant Adaptation: Ensuring Viral Safety and Regulatory Compliance”, addressed the industrial experience in the continuous adaptation of vaccines to new variants, as well as the challenges related to viral safety and regulatory compliance in these processes.
During her intervention, Clara Panosa highlighted how platform-based approaches enable faster vaccine development while maintaining high standards of quality and safety, through risk-based control strategies and close alignment with regulatory requirements.
